Increased frequency of CD4
chronic lung allograft dysfunction and graft survival
lung transplantation
regulatory t cell
Journal
Transplant international : official journal of the European Society for Organ Transplantation
ISSN: 1432-2277
Titre abrégé: Transpl Int
Pays: Switzerland
ID NLM: 8908516
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
06
02
2019
revised:
04
05
2019
accepted:
20
12
2019
pubmed:
7
1
2020
medline:
25
6
2021
entrez:
7
1
2020
Statut:
ppublish
Résumé
In this retrospective study, we analyzed the presence of any association of three CD4
Substances chimiques
Interleukin-2 Receptor alpha Subunit
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
503-516Subventions
Organisme : Novartis
Organisme : Astellas
Organisme : Deutsche Forschungsgemeinschaft
ID : SFB 738
Organisme : German Centre for Lung Research
Informations de copyright
© 2020 Steunstichting ESOT.
Références
Chambers DC, Yusen RD, Cherikh WS, et al. The Registry of the International Society for Heart and Lung Transplantation: thirty-fourth adult lung and heart-lung transplantation report-2017; focus theme: allograft ischemic time. J Heart Lung Transplant 2017; 36: 1047.
DerHovanessian A, Wallace WD, Lynch JP 3rd, Belperio JA, Weigt SS. Chronic lung allograft dysfunction: evolving concepts and therapies. Semin Respir Crit Care Med 2018; 39: 155.
Sakaguchi S, Ono M, Setoguchi R, et al. Foxp3+CD24+CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006; 212: 8.
Wood KJ, Bushell WA, Hester J. Regulatory immune cells in transplantation. Nat Rev Immunol 2012; 12: 417.
Khan MA. T regulatory cell-mediated immunotherapy for solid organ transplantation: a clinical perspective. Mol Med 2016; 22: 892.
Hall BM. CD4+CD25+ T regulatory cells in transplantation tolerance: 25 years on. Transplantation 2016; 100: 2533.
Kanamori M, Nakatsukasa H, Okada M, Lu Q, Yoshimura A. Induced regulatory T cells: their development, stability, and applications. Trends Immunol 2016; 37: 803.
Lu L, Barbi J, Pan F. The regulation of immune tolerance by FOXP3. Nat Rev Immunol 2017; 17: 703.
Kawai K, Uchiyama M, Hester J, Wood K, Issa F. Regulatory T cells for tolerance. Hum Immunol 2018; 79: 294.
Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 2007; 13: 108.
Warnecke G, Bushell A, Nadig SN, Wood KJ. Regulation of transplant arteriosclerosis by CD25+CD4+ T cells generated to alloantigen in vivo. Transplantation 2007; 83: 1459.
Zhou W, Zhou X, Gaowa S, et al. The critical role of induced CD4+FoxP3+ regulatory cells in suppression of interleukin-17 production and attenuation of mouse orthotopic lung allograft rejection. Transplantation 2015; 99: 1356.
Chiu S, Fernandez R, Subramanian V, et al. Lung injury combined with loss of regulatory T cells leads to de novo lung-restricted autoimmunity. J Immunol 2016; 197: 51.
Sommer W, Knöfel AK, Madrahimov N, et al. Allogenic CD4+CD25high T cells regulate obliterative bronchiolitis of heterotopic bronchus allografts in both porcinized and humanized mouse models. Transplantation 2015; 99: 482.
Avsar M, Jansson K, Sommer W, et al. Augmentation of transient donor cell chimerism and alloantigen-specific regulation of lung transplants in miniature swine. Am J Transplant 2016; 16: 1371.
Siemeni T, Knöfel AK, Madrahimov N, et al. In vivo development of transplant arteriosclerosis in humanized mice reflects alloantigen recognition and peripheral Treg phenotype of lung transplant recipients. Am J Transplant 2016; 16: 3150.
Siemeni T, Knöfel AK, Fabio I, et al. Transplant arteriosclerosis in humanized mice reflects chronic lung allograft dysfunction and is controlled by regulatory T cells. J Thorac Cardiovasc Surg 2019; 157: 2528.
Dial CF, Tune MK, Doerschuk CM, Mock JR. Foxp3+ regulatory T cell expression of keratinocyte growth factor enhances lung epithelial proliferation. Am J Respir Cell Mol Biol 2017; 57: 162.
Neujahr DC, Cardona AC, Ulukpo O, et al. Dynamics of human regulatory T cells in lung lavages of lung transplant recipients. Transplantation 2009; 88: 521.
Bhorade SM, Chen H, Molinero L, et al. Decreased percentage of CD4+FoxP3+ cells in bronchoalveolar lavage from lung transplant recipients correlates with development of bronchiolitis obliterans syndrome. Transplantation 2010; 90: 540.
Gregson AL, Hoji A, Palchevskiy V, et al. Protection against bronchiolitis obliterans syndrome is associated with allograft CCR7+CD45RA- T regulatory cells. PLoS ONE 2010; 5: e11354.
Nakagiri T, Warnecke G, Avsar M, et al. Lung function early after lung transplantation is correlated with the frequency of regulatory T cells. Surg Today 2012; 42: 250.
Krustrup D, Iversen M, Martinussen T, Henrik H. Schultz l, Andersen CB. The number of FoxP3+ cells in transbronchial lung allograft biopsies does not predict bronchiolitis obliterans syndrome within the first five years after transplantation. Clin Transplant 2015; 29: 179.
Greenland JR, Wong CM, Ahuja R, et al. Donor-reactive regulatory T cell frequency increases during acute cellular rejection of lung allografts. Transplantation 2016; 100: 2090.
Piloni D, Morosini M, Magni S, et al. Analysis of long term CD4+CD25highCD127- T-reg cells kinetics in peripheral blood of lung transplant recipients. BMC Pulm Med 2017; 17: 102.
Salman J, Ius F, Knoefel AK, et al. Association of higher CD4+CD25highCD127low, FoxP3+, and IL-2+ T cell frequencies early after lung transplantation with less chronic lung allograft dysfunction at two years. Am J Transplant 2017; 17: 1637.
Durand M, Lacoste P, Danger R, et al. High circulating CD4+CD25hiFOXP3+ T-cell sub-population is associated with development of bronchiolitis obliterans syndrome. J Heart Lung Transplant 2018; 37: 770.
Snell GI, Yusen RD, Weill D, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part I: Definition and grading - A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2017; 36: 1097.
Ius F, Sommer W, Tudorache I, et al. Preemptive treatment with therapeutic plasma exchange and rituximab for early donor-specific antibodies after lung transplantation. J Heart Lung Transplant 2015; 34: 50.
Ius F, Sommer W, Kieneke D, et al. IgM-enriched human intravenous immunoglobulin-based treatment of patients with early donor specific anti-HLA antibodies after lung transplantation. Transplantation 2016; 100: 2682-2692.
Ius F, Verboom M, Sommer W, et al. Preemptive treatment of early donor specific antibodies with IgA- and IgM-enriched intravenous human immunoglobulins in lung transplantation. Am J Transplant 2018; 18: 2295.
Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007; 26: 1229.
Verleden SE, Todd JL, Sato D, et al. Impact of CLAD phenotype on survival after lung re-transplantation: a multicenter study. Am J Transplant 2015; 15: 2223.
Levine DJ, Glanville AR, Aboyoun C, et al. Antibody-mediated rejection of the lung: a consensus report of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2016; 35: 397.
Lederer DJ, Bell SC, Branson RD, et al. Control of confounding and reporting of results in causal inference studies. Guidance for authors from editors of respiratory, sleep, and critical Care Journals. Ann Am Thorac Soc 2019; 16: 22.
Treede H, Glanville AR, Klepetko W, et al. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: results of a prospective, randomized international trial in lung transplantation. J Heart Lung Transplant 2012; 31: 797.
Whitson BA, Prekker ME, Herrington CS, et al. Primary graft dysfunction and long-term pulmonary function after lung transplantation. J Heart Lung Transplant 2007; 10: 1004.
Smith JD, Ibrahim MW, Newell H, et al. Pre-transplant donor HLA-specific antibodies: characteristics causing detrimental effects on survival after lung transplantation. J Heart Lung Transplant 2014; 33: 1074.
Ius F, Sommer W, Tudorache I, et al. Five-year experience with intraoperative extracorporeal membrane oxygenation in lung transplantation: Indications and midterm results. J Heart Lung Transplant 2016; 35: 39.
Ius F, Sommer W, Tudorache I, et al. Early-donor-specific antibodies in lung transplantation: risk factors and impact on survival. J Heart Lung Transplant 2014; 33: 1255.
Heinze G, Dunkler D. Five myths about variable selection. Transpl Int 2017; 30: 6.
Dunkler D, Plischke M, Leffondré K, Heinze G. Augmented backward elimination: a pragmatic and purposeful way to develop statistical models. PLoS ONE 2014; 9: e113677.
Nadig SN, Wieckiewicz J, Wu DC, et al. In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells. Nat Med 2010; 16: 809.
Noyan F, Lee YS, Zimmermann K, et al. Isolation of human antigen-specific regulatory T cells with high suppressive function. Eur J Immunol 2014; 44: 2592.
Nafady-Hego H, Li Y, Ohe H, et al. Utility of CD127 combined with FOXP3 for identification of operational tolerance after liver transplantation. Transpl Immunol 2016; 36: 1.
Liu W, Putnam AL, Xu-yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006; 203: 1701.
Furukawa A, Wisel SA, Tang Q. Impact of immune-modulatory drugs on Treg. Transplantation 2016; 100: 2288.
Jordan SC, Toyoda M, Vo AA. Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation. Expert Rev Clin Immunol 2011; 7: 341.
Whitehouse G, Gray E, Mastoridis S, et al. IL-2 therapy restores regulatory T-cell dysfunction induced by calcineurin inhibitors. Proc Natl Acad Sci USA 2017; 114: 7083.